;PMID: 10490922
;source_file_866.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..208] = [t:51..208]
;2)section:[e:212..231] = [t:212..231]
;3)section:[e:235..354] = [t:235..354]
;4)sentence:[e:358..518] = [t:358..518]
;5)sentence:[e:520..838] = [t:520..838]
;6)sentence:[e:839..1047] = [t:839..1047]
;7)sentence:[e:1048..1194] = [t:1048..1194]
;8)sentence:[e:1195..1405] = [t:1195..1405]
;9)sentence:[e:1406..1530] = [t:1406..1530]
;10)sentence:[e:1531..1690] = [t:1531..1690]
;11)sentence:[e:1691..1810] = [t:1691..1810]
;12)sentence:[e:1811..1948] = [t:1811..1948]
;13)sentence:[e:1949..2147] = [t:1949..2147]
;14)sentence:[e:2148..2323] = [t:2148..2323]
;15)section:[e:2327..2372] = [t:2327..2372]

;section 0 Span:0..45
;J Pharmacol Exp Ther. 1999 Oct;291(1):335-44.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[22..26] 1999)
        (CC:[27..35] Oct;291-LRB-) (CD:[35..36] 1) (-RRB-:[36..37] -RRB-)
        (CD:[37..41] :335) (HYPH:[41..42] -) (CD:[42..44] 44) (.:[44..45] .)))

;sentence 1 Span:51..208
;Hypoxia and alkalinization inhibit endothelium-derived nitric oxide but not 
;endothelium-derived hyperpolarizing factor responses in porcine coronary
;artery.
;[86..118]:substance:"endothelium-derived nitric oxide"
;[128..170]:substance:"endothelium-derived hyperpolarizing factor"
(SENT
  (S-HLN
    (NP-SBJ (NN:[51..58] Hypoxia) (CC:[59..62] and) (NN:[63..77] alkalinization))
    (VP
      (VP (VBP:[78..85] inhibit)
        (NP=1
          (ADJP (NN:[86..97] endothelium) (HYPH:[97..98] -)
                (VBN:[98..105] derived))
          (JJ:[106..112] nitric) (NN:[113..118] oxide)))
      (VP (CC:[119..122] but) (RB:[123..126] not)
        (NP=1
          
          (ADJP (NN:[128..139] endothelium) (HYPH:[139..140] -)
                (VBN:[140..147] derived))
          (VBG:[148..163] hyperpolarizing) (NN:[164..170] factor)
          (NNS:[171..180] responses))
        (PP-LOC (IN:[181..183] in)
          (NP (JJ:[184..191] porcine) (JJ:[192..200] coronary)
              (NN:[201..207] artery)))))
    (.:[207..208] .)))

;section 2 Span:212..231
;Shimizu S, Paul RJ.
(SEC
  (FRAG (NNP:[212..219] Shimizu) (NNP:[220..222] S,) (NNP:[223..227] Paul)
        (NNP:[228..231] RJ.)))

;section 3 Span:235..354
;Department of Molecular and Cellular Physiology, University of Cincinnati, 
;College of Medicine, Cincinnati, Ohio, USA.
(SEC
  (FRAG (NNP:[235..245] Department) (IN:[246..248] of)
        (NNP:[249..258] Molecular) (CC:[259..262] and) (NNP:[263..271] Cellular)
        (NNP:[272..282] Physiology) (,:[282..283] ,) (NNP:[284..294] University)
        (IN:[295..297] of) (NNP:[298..308] Cincinnati) (,:[308..309] ,)
        (NNP:[311..318] College) (IN:[319..321] of) (NNP:[322..330] Medicine)
        (,:[330..331] ,) (NNP:[332..342] Cincinnati) (,:[342..343] ,)
        (NNP:[344..348] Ohio) (,:[348..349] ,) (NNP:[350..353] USA)
        (.:[353..354] .)))

;sentence 4 Span:358..518
;We investigated the mechanisms by which hypoxia and alkalinization inhibit
;the  endothelium-dependent relaxation to Substance P (SP) in porcine coronary
;artery.
;[474..485]:substance:"Substance P"
;[487..489]:substance:"SP"
(SENT
  (S
    (NP-SBJ (PRP:[358..360] We))
    (VP (VBD:[361..373] investigated)
      (NP
        (NP (DT:[374..377] the) (NNS:[378..388] mechanisms))
        (SBAR
          (WHPP-1 (IN:[389..391] by)
            (WHNP (WDT:[392..397] which)))
          (S
            (NP-SBJ (NN:[398..405] hypoxia) (CC:[406..409] and)
                    (NN:[410..424] alkalinization))
            (VP (VBP:[425..432] inhibit)
              (NP
                (NP (DT:[433..436] the)
                  (ADJP (NN:[438..449] endothelium) (HYPH:[449..450] -)
                        (JJ:[450..459] dependent))
                  (NN:[460..470] relaxation))
                (PP (TO:[471..473] to)
                  (NP
                    (NP (NN:[474..483] Substance) (NN:[484..485] P))
                    (NP (-LRB-:[486..487] -LRB-) (NN:[487..489] SP)
                        (-RRB-:[489..490] -RRB-)))))
              (PP-LOC (IN:[491..493] in)
                (NP (JJ:[494..501] porcine) (JJ:[502..510] coronary)
                    (NN:[511..517] artery)))
              (PP-MNR-1 (-NONE-:[517..517] *T*)))))))
    (.:[517..518] .)))

;sentence 5 Span:520..838
;In a KCl contracture, the major component of the SP response is 
;endothelium-derived nitric oxide (EDNO), whereas with receptor-mediated 
;9,11-dideoxy-llalpha, 9alpha-epoxymethanoprostaglandin F(2alpha) (U46619) 
;stimulation, the SP response is dependent on both EDNO and
;endothelium-derived  hyperpolarization factor.
;[525..528]:substance:"KCl"
;[569..571]:substance:"SP"
;[585..617]:substance:"endothelium-derived nitric oxide"
;[619..623]:substance:"EDNO"
;[639..647]:substance:"receptor"
;[658..678]:substance:"9,11-dideoxy-llalpha"
;[680..714]:substance:"9alpha-epoxymethanoprostaglandin F"
;[715..721]:substance:"2alpha"
;[724..730]:substance:"U46619"
;[750..752]:substance:"SP"
;[783..787]:substance:"EDNO"
;[792..837]:substance:"endothelium-derived  hyperpolarization factor"
(SENT
  (S
    (PP (IN:[520..522] In)
      (NP (DT:[523..524] a) (NN:[525..528] KCl) (NN:[529..540] contracture)))
    (,:[540..541] ,)
    (NP-SBJ
      (NP (DT:[542..545] the) (JJ:[546..551] major) (NN:[552..561] component))
      (PP (IN:[562..564] of)
        (NP (DT:[565..568] the) (NN:[569..571] SP) (NN:[572..580] response))))
    (VP (VBZ:[581..583] is)
      (NP-PRD
        (NP
          (ADJP (NN:[585..596] endothelium) (HYPH:[596..597] -)
                (VBN:[597..604] derived))
          (JJ:[605..611] nitric) (NN:[612..617] oxide))
        (NP (-LRB-:[618..619] -LRB-) (NN:[619..623] EDNO)
            (-RRB-:[623..624] -RRB-)))
      (,:[624..625] ,)
      (SBAR-ADV (IN:[626..633] whereas)
        (S
          (PP (IN:[634..638] with)
            (NP
              (ADJP (NN:[639..647] receptor) (HYPH:[647..648] -)
                    (VBN:[648..656] mediated))
              (NML
                (NML (NN:[658..678] 9,11-dideoxy-llalpha) (,:[678..679] ,)
                   (NN:[680..712] 9alpha-epoxymethanoprostaglandin)
                   (NN:[713..714] F)
                  (-LRB-:[714..715] -LRB-) (NN:[715..721] 2alpha)
                   (-RRB-:[721..722] -RRB-))
                (NML (-LRB-:[723..724] -LRB-) (NN:[724..730] U46619)
                     (-RRB-:[730..731] -RRB-)))
              (NN:[733..744] stimulation)))
          (,:[744..745] ,)
          (NP-SBJ (DT:[746..749] the) (NN:[750..752] SP)
                  (NN:[753..761] response))
          (VP (VBZ:[762..764] is)
            (ADJP-PRD (JJ:[765..774] dependent)
              (PP (IN:[775..777] on)
                (NP (CC:[778..782] both)
                  (NP (NN:[783..787] EDNO))
                  (CC:[788..791] and)
                  (NP
                    (ADJP (NN:[792..803] endothelium) (HYPH:[803..804] -)
                          (VBN:[804..811] derived))
                    (NN:[813..830] hyperpolarization) (NN:[831..837] factor)))))))))
    (.:[837..838] .)))

;sentence 6 Span:839..1047
;Intracellular alkalinization by NH(4)Cl reduced the  peak of SP responses
;when arteries were contracted with KCl, whereas with U46619  stimulation, the
;peak was little effected but the duration was shortened.
;[871..878]:substance:"NH(4)Cl"
;[900..902]:substance:"SP"
;[948..951]:substance:"KCl"
;[966..972]:substance:"U46619"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[839..852] Intracellular) (NN:[853..867] alkalinization))
      (PP (IN:[868..870] by)
        (NP (NN:[871..878] NH-LRB-4-RRB-Cl))))
    (VP (VBD:[879..886] reduced)
      (NP
        (NP (DT:[887..890] the) (NN:[892..896] peak))
        (PP (IN:[897..899] of)
          (NP (NN:[900..902] SP) (NNS:[903..912] responses))))
      (SBAR-ADV
        (WHADVP-3 (WRB:[913..917] when))
        (S
          (NP-SBJ-4 (NNS:[918..926] arteries))
          (VP (VBD:[927..931] were)
            (VP (VBN:[932..942] contracted)
              (NP-4 (-NONE-:[942..942] *))
              (PP-MNR (IN:[943..947] with)
                (NP (NN:[948..951] KCl)))
              (ADVP-TMP-3 (-NONE-:[951..951] *T*))))))
      (,:[951..952] ,)
      (SBAR-ADV (IN:[953..960] whereas)
        (S
          (S
            (PP (IN:[961..965] with)
              (NP (NN:[966..972] U46619) (NN:[974..985] stimulation)))
            (,:[985..986] ,)
            (NP-SBJ-2 (DT:[987..990] the) (NN:[991..995] peak))
            (VP (VBD:[996..999] was)
              (ADVP (JJ:[1000..1006] little))
              (VP (VBN:[1007..1015] effected)
                (NP-2 (-NONE-:[1015..1015] *)))))
          (CC:[1016..1019] but)
          (S
            (NP-SBJ-1 (DT:[1020..1023] the) (NN:[1024..1032] duration))
            (VP (VBD:[1033..1036] was)
              (VP (VBN:[1037..1046] shortened)
                (NP-1 (-NONE-:[1046..1046] *))))))))
    (.:[1046..1047] .)))

;sentence 7 Span:1048..1194
;In  endothelial cell-denuded arteries, alkalinization with NH(4)Cl shifted
;the  sodium nitroprusside concentration-relaxation relations rightward.
;[1107..1114]:substance:"NH(4)Cl"
;[1128..1148]:substance:"sodium nitroprusside"
(SENT
  (S
    (PP-LOC (IN:[1048..1050] In)
      (NP
        (ADJP
          (NML (JJ:[1052..1063] endothelial) (NN:[1064..1068] cell))
          (HYPH:[1068..1069] -) (VBN:[1069..1076] denuded))
        (NNS:[1077..1085] arteries)))
    (,:[1085..1086] ,)
    (NP-SBJ
      (NP (NN:[1087..1101] alkalinization))
      (PP (IN:[1102..1106] with)
        (NP (NN:[1107..1114] NH-LRB-4-RRB-Cl))))
    (VP (VBD:[1115..1122] shifted)
      (NP (DT:[1123..1126] the)
        (NML
          (NML
            (NML (NN:[1128..1134] sodium) (NN:[1135..1148] nitroprusside))
            (NN:[1149..1162] concentration))
          (PP (HYPH:[1162..1163] -)
            (NP (NN:[1163..1173] relaxation))))
        (NNS:[1174..1183] relations))
      (ADVP (RB:[1184..1193] rightward)))
    (.:[1193..1194] .)))

;sentence 8 Span:1195..1405
;The effects  of NH(4)Cl in SP- and sodium nitroprusside-induced relaxations
;were attenuated  by decreasing extracellular pH (pH(o)) from 7.4 to 7.2,
;which normalized  intracellular pH (pH(i)) to control levels.
;[1211..1218]:substance:"NH(4)Cl"
;[1222..1224]:substance:"SP"
;[1230..1250]:substance:"sodium nitroprusside"
;[1316..1318]:quantitative-name:"pH"
;[1320..1325]:quantitative-name:"pH(o)"
;[1332..1342]:quantitative-value:"7.4 to 7.2"
;[1376..1378]:quantitative-name:"pH"
;[1380..1385]:quantitative-name:"pH(i)"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1195..1198] The) (NNS:[1199..1206] effects))
      (PP (IN:[1208..1210] of)
        (NP (NN:[1211..1218] NH-LRB-4-RRB-Cl)))
      (PP (IN:[1219..1221] in)
        (NP
          (NP
            (ADJP (NN:[1222..1224] SP) (HYPH:[1224..1225] -)
              (ADJP-1 (-NONE-:[1225..1225] *P*)))
            (NML-4 (-NONE-:[1225..1225] *P*)))
          (CC:[1226..1229] and)
          (NP
            (ADJP
              (NML (NN:[1230..1236] sodium) (NN:[1237..1250] nitroprusside))
              (HYPH:[1250..1251] -)
              (ADJP-1 (VBN:[1251..1258] induced)))
            (NML-4 (NNS:[1259..1270] relaxations))))))
    (VP (VBD:[1271..1275] were)
      (VP (VBN:[1276..1286] attenuated)
        (NP-2 (-NONE-:[1286..1286] *))
        (PP-MNR (IN:[1288..1290] by)
          (S-NOM
            (NP-SBJ (-NONE-:[1290..1290] *))
            (VP (VBG:[1291..1301] decreasing)
              (NP
                (NP (JJ:[1302..1315] extracellular) (NN:[1316..1318] pH))
                (NP (-LRB-:[1319..1320] -LRB-) (NN:[1320..1325] pH-LRB-o-RRB-)
                    (-RRB-:[1325..1326] -RRB-)))
              (PP (IN:[1327..1331] from)
                (NP (CD:[1332..1335] 7.4)))
              (PP (TO:[1336..1338] to)
                (NP (CD:[1339..1342] 7.2)))
              (,:[1342..1343] ,)
              (SBAR-ADV
                (WHNP-3 (WDT:[1344..1349] which))
                (S
                  (NP-SBJ-3 (-NONE-:[1349..1349] *T*))
                  (VP (VBD:[1350..1360] normalized)
                    (NP
                      (NP (JJ:[1362..1375] intracellular) (NN:[1376..1378] pH))
                      (NP (-LRB-:[1379..1380] -LRB-)
                          (NN:[1380..1385] pH-LRB-i-RRB-)
                          (-RRB-:[1385..1386] -RRB-)))
                    (PP (TO:[1387..1389] to)
                      (NP (NN:[1390..1397] control) (NNS:[1398..1404] levels)))))))))))
    (.:[1404..1405] .)))

;sentence 9 Span:1406..1530
;In contrast, in U46619 contractures,  the SP response in the presence of a NO
;synthase inhibitor was unaffected by  NH(4)Cl.
;[1422..1428]:substance:"U46619"
;[1448..1450]:substance:"SP"
;[1481..1492]:substance:"NO synthase"
;[1493..1502]:substance:"inhibitor"
;[1522..1529]:substance:"NH(4)Cl"
(SENT
  (S
    (PP (IN:[1406..1408] In)
      (NP (NN:[1409..1417] contrast)))
    (,:[1417..1418] ,)
    (PP (IN:[1419..1421] in)
      (NP (NN:[1422..1428] U46619) (NNS:[1429..1441] contractures)))
    (,:[1441..1442] ,)
    (NP-SBJ
      (NP (DT:[1444..1447] the) (NN:[1448..1450] SP) (NN:[1451..1459] response))
      (PP (IN:[1460..1462] in)
        (NP
          (NP (DT:[1463..1466] the) (NN:[1467..1475] presence))
          (PP (IN:[1476..1478] of)
            (NP (DT:[1479..1480] a)
              (NML (NN:[1481..1483] NO) (NN:[1484..1492] synthase))
              (NN:[1493..1502] inhibitor))))))
    (VP (VBD:[1503..1506] was)
      (ADJP-PRD (JJ:[1507..1517] unaffected)
        (PP (IN:[1518..1520] by)
          (NP (NN:[1522..1529] NH-LRB-4-RRB-Cl)))))
    (.:[1529..1530] .)))

;sentence 10 Span:1531..1690
;Moreover, hypoxia blunted but did not abolish the responses to SP for  U46619
;contractures; addition of KCl, however, abolished the SP response under 
;hypoxia.
;[1594..1596]:substance:"SP"
;[1602..1608]:substance:"U46619"
;[1635..1638]:substance:"KCl"
;[1663..1665]:substance:"SP"
(SENT
  (S
    (S
      (ADVP (RB:[1531..1539] Moreover))
      (,:[1539..1540] ,)
      (NP-SBJ (NN:[1541..1548] hypoxia))
      (VP
        (VP (VBD:[1549..1556] blunted)
          (NP-1 (-NONE-:[1556..1556] *RNR*)))
        (CC:[1557..1560] but)
        (VP (VBD:[1561..1564] did) (RB:[1565..1568] not)
          (VP (VB:[1569..1576] abolish)
            (NP-1 (-NONE-:[1576..1576] *RNR*))))
        (NP-1
          (NP (DT:[1577..1580] the) (NNS:[1581..1590] responses))
          (PP (TO:[1591..1593] to)
            (NP (NN:[1594..1596] SP))))
        (PP (IN:[1597..1600] for)
          (NP (NN:[1602..1608] U46619) (NNS:[1609..1621] contractures)))))
    (::[1621..1622] ;)
    (S
      (NP-SBJ
        (NP (NN:[1623..1631] addition))
        (PP (IN:[1632..1634] of)
          (NP (NN:[1635..1638] KCl))))
      (,:[1638..1639] ,)
      (ADVP (RB:[1640..1647] however))
      (,:[1647..1648] ,)
      (VP (VBD:[1649..1658] abolished)
        (NP (DT:[1659..1662] the) (NN:[1663..1665] SP)
            (NN:[1666..1674] response))
        (PP (IN:[1675..1680] under)
          (NP (NN:[1682..1689] hypoxia)))))
    (.:[1689..1690] .)))

;sentence 11 Span:1691..1810
;Endothelial [Ca(2+)](i) was measured with fura-2 differentially loaded  only
;into endothelial cells on intact arteries.
;[1704..1710]:substance:"Ca(2+)"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1691..1702] Endothelial) (-LRB-:[1703..1704] -LSB-)
              (NN:[1704..1710] Ca-LRB-2+-RRB-) (-RRB-:[1710..1711] -RSB-)
              (-LRB-:[1711..1712] -LRB-) (NN:[1712..1713] i)
              (-RRB-:[1713..1714] -RRB-))
    (VP (VBD:[1715..1718] was)
      (VP (VBN:[1719..1727] measured)
        (NP-1 (-NONE-:[1727..1727] *))
        (PP (IN:[1728..1732] with)
          (NP
            (NP (NN:[1733..1739] fura-2))
            (VP
              (ADVP (RB:[1740..1754] differentially))
              (VBN:[1755..1761] loaded)
              (NP (-NONE-:[1761..1761] *))
              (PP
                (ADVP (RB:[1763..1767] only))
                (IN:[1768..1772] into)
                (NP
                  (NP (JJ:[1773..1784] endothelial) (NNS:[1785..1790] cells))
                  (PP-LOC (IN:[1791..1793] on)
                    (NP (JJ:[1794..1800] intact) (NNS:[1801..1809] arteries))))))))))
    (.:[1809..1810] .)))

;sentence 12 Span:1811..1948
;Despite the attenuation of the  SP response in KCl contractures by NH(4)Cl or
;hypoxia, endothelial [Ca(2+)](i)  responses were unchanged.
;[1843..1845]:substance:"SP"
;[1858..1861]:substance:"KCl"
;[1878..1885]:substance:"NH(4)Cl"
;[1911..1917]:substance:"Ca(2+)"
(SENT
  (S
    (PP (IN:[1811..1818] Despite)
      (NP
        (NP (DT:[1819..1822] the) (NN:[1823..1834] attenuation))
        (PP (IN:[1835..1837] of)
          (NP (DT:[1838..1841] the) (NN:[1843..1845] SP)
              (NN:[1846..1854] response)))
        (PP (IN:[1855..1857] in)
          (NP (NN:[1858..1861] KCl) (NNS:[1862..1874] contractures)))
        (PP (IN:[1875..1877] by)
          (NP (NN:[1878..1885] NH-LRB-4-RRB-Cl) (CC:[1886..1888] or)
              (NN:[1889..1896] hypoxia)))))
    (,:[1896..1897] ,)
    (NP-SBJ
      (NML (JJ:[1898..1909] endothelial) (-LRB-:[1910..1911] -LSB-)
           (NN:[1911..1917] Ca-LRB-2+-RRB-) (-RRB-:[1917..1918] -RSB-)
           (-LRB-:[1918..1919] -LRB-) (NN:[1919..1920] i)
           (-RRB-:[1920..1921] -RRB-))
      (NNS:[1923..1932] responses))
    (VP (VBD:[1933..1937] were)
      (ADJP-PRD (JJ:[1938..1947] unchanged)))
    (.:[1947..1948] .)))

;sentence 13 Span:1949..2147
;Our results suggest that hypoxia and alkalinization  inhibit EDNO but not
;endothelium-derived hyperpolarization factor relaxations  through a
;mechanism(s) not involving endothelial cell [Ca(2+)](i).
;[2010..2014]:substance:"EDNO"
;[2023..2067]:substance:"endothelium-derived hyperpolarization factor"
;[2136..2142]:substance:"Ca(2+)"
(SENT
  (S
    (NP-SBJ (PRP$:[1949..1952] Our) (NNS:[1953..1960] results))
    (VP (VBP:[1961..1968] suggest)
      (SBAR (IN:[1969..1973] that)
        (S
          (NP-SBJ (NN:[1974..1981] hypoxia) (CC:[1982..1985] and)
                  (NN:[1986..2000] alkalinization))
          (VP
            (VP (VBP:[2002..2009] inhibit)
              (NP=1 (NN:[2010..2014] EDNO)))
            (CC:[2015..2018] but)
            (VP (RB:[2019..2022] not)
              (NP=1
                
                (ADJP (NN:[2023..2034] endothelium) (HYPH:[2034..2035] -)
                      (VBN:[2035..2042] derived))
                (NN:[2043..2060] hyperpolarization) (NN:[2061..2067] factor)
                (NNS:[2068..2079] relaxations))
              (PP-MNR (IN:[2081..2088] through)
                (NP
                  (NP (DT:[2089..2090] a) (NN:[2091..2103] mechanism-LRB-s-RRB-))
                  (VP (RB:[2104..2107] not) (VBG:[2108..2117] involving)
                    (NP (JJ:[2118..2129] endothelial) (NN:[2130..2134] cell)
                        (-LRB-:[2135..2136] -LSB-)
                        (NN:[2136..2142] Ca-LRB-2+-RRB-)
                        (-RRB-:[2142..2143] -RSB-) (-LRB-:[2143..2144] -LRB-)
                        (NN:[2144..2145] i) (-RRB-:[2145..2146] -RRB-))))))))))
    (.:[2146..2147] .)))

;sentence 14 Span:2148..2323
;Inhibition of  EDNO relaxation by alkalinization with NH(4)Cl is likely to
;occur at the level  of activation of guanylate cyclase and/or at a step
;downstream in smooth muscle.
;[2163..2167]:substance:"EDNO"
;[2202..2209]:substance:"NH(4)Cl"
;[2260..2277]:substance:"guanylate cyclase"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[2148..2158] Inhibition))
      (PP (IN:[2159..2161] of)
        (NP (NN:[2163..2167] EDNO) (NN:[2168..2178] relaxation)))
      (PP (IN:[2179..2181] by)
        (NP
          (NP (NN:[2182..2196] alkalinization))
          (PP (IN:[2197..2201] with)
            (NP (NN:[2202..2209] NH-LRB-4-RRB-Cl))))))
    (VP (VBZ:[2210..2212] is)
      (ADJP-PRD (JJ:[2213..2219] likely)
        (S
          (NP-SBJ-1 (-NONE-:[2219..2219] *))
          (VP (TO:[2220..2222] to)
            (VP (VB:[2223..2228] occur)
              (PP
                (PP (IN:[2229..2231] at)
                  (NP
                    (NP (DT:[2232..2235] the) (NN:[2236..2241] level))
                    (PP (IN:[2243..2245] of)
                      (NP
                        (NP (NN:[2246..2256] activation))
                        (PP (IN:[2257..2259] of)
                          (NP (NN:[2260..2269] guanylate)
                              (NN:[2270..2277] cyclase)))))))
                (CC:[2278..2284] and/or)
                (PP (IN:[2285..2287] at)
                  (NP
                    (NP (DT:[2288..2289] a) (NN:[2290..2294] step)
                        (RB:[2295..2305] downstream))
                    (PP-LOC (IN:[2306..2308] in)
                      (NP (JJ:[2309..2315] smooth) (NN:[2316..2322] muscle)))))))))))
    (.:[2322..2323] .)))

;section 15 Span:2327..2372
;PMID: 10490922 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2327..2331] PMID) (::[2331..2332] :) (CD:[2333..2341] 10490922)
        (IN:[2342..2343] -LSB-) (NNP:[2343..2349] PubMed) (HYPH:[2350..2351] -)
        (JJ:[2352..2359] indexed) (IN:[2360..2363] for)
        (NNP:[2364..2372] MEDLINE-RSB-)))
